Rajni Kannan, BS, MS, RN, ANP-BC, Perlmutter Cancer Center at NYU Langone, gives an overview of immune related adverse events (IRAEs).
Rajni Kannan, BS, MS, RN, ANP-BC, Perlmutter Cancer Center at NYU Langone, gives an overview of immune related adverse events (IRAEs).
Kannan says the adverse events seen in patients taking immunotherapy agents are classified differently than other adverse events. These new immunotherapy agents are activating T cells that not only go after the cancer, but also to work on the healthy tissues.
The most common side effects seen with immunotherapies are diarrhea and rash but patients may also experience pseudo hepatitis, endocrinopathies, and eye toxicities.
Ibrutinib Plus Prednisone Does Not Improve Response Rates in cGVHD
February 2nd 2023First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
2 Clarke Drive
Cranbury, NJ 08512